Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person1
uniQure N.V.
Company
Primary record8
uniQure N.V. filed 8-K
Item 2.02 Results of Operations and Financial Condition. On November 4, 2026, uniQure N.V. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2026 and providing a
uniQure N.V. filed 4
SEC form 4 filed by uniQure N.V. (CIK 1590560) on 2026-11-03.
uniQure N.V. filed 8-K
Item 7.01 Regulation FD Disclosure. On November 2, 2026, uniQure N.V. (the “ Company ”) issued a press release announcing the U.S. Food and Drug Administration (“ FDA ”) has accepted for review the Biologics License Appl
JPMORGAN CHASE & CO filed SCHEDULE 13G/A
0000019617-26-000387.txt : 20261016 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0000019617 XXXXXXXX LIVE 1 Ordinary Shares, par value 0.05 09/30/2026 0001590560 uniQure N.V. N90064101 Paasheuvelweg 25a 1105 BP
uniQure N.V. filed 8-K
Item 7.01 Regulation FD Disclosure. On September 29, 2026, uniQure N.V. (the Company ) presented an update of its ongoing clinical trials of AMT-130 (the Presentation ) and issued a press release which summarizes the Pre
uniQure N.V. filed 8-K
Item 7.01 Regulation FD Disclosure. On September 2, 2026, uniQure N.V. (the “ Company ”) issued a press release announcing the submission of a Biologics License Application to the United States Food and Drug Administrati
uniQure N.V. filed SCHEDULE 13G
, as amended, the beneficial owner of the Shares reported herein. The address of the business office of each of the Reporting Persons is 40 10th Avenue, Floor 7, New York, New York 10014. RTW Investments is a Delaware li
uniQure N.V. filed SCHEDULE 13G/A
0001446580-26-000102.txt : 20260814 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0001446580-26-000042 0001446580 XXXXXXXX LIVE 1 Ordinary Shares, EUR 0.05 par value per share 06/30/2026 0001590560 uniQure N.V. N